ArticleiLIVER2023
Efficiency and safety of sofosbuvir in Bangladeshi children with chronic hepatitis C virus infection.
Article in iLIVER, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of sofosbuvir-based therapies for treating HCV in children: observations from a real-world setting.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Currently, treatment with oral direct-acting antivirals is recommended for all hepatitis C virus (HCV)-infected pediatric patients. The aim of this study was to evaluate the efficacy and safety of sofosbuvir and ribavirin combination therapy for children and adolescents in Bangladesh who are living with chronic HCV infection. Methods: An experimental study was performed from January 2021 to December 2022. HCV polymerase chain reaction (PCR)-positive thalassemic children, who were 6-18 years of age, were enrolled by consecutive nonprobability sampling. Clinical features were recorded, and investigations were performed. All patients were initially treated with sofosbuvir (200 mg for 6- to 11-year-olds and 400 mg for 12- to 18-year-olds) and ribavirin (10-15 mg/kg/day) and were assessed clinically on a four-weekly basis, along with liver-function testing. The total duration of therapy was 24 weeks. HCV PCR was done at the end of treatment and 12 weeks after the completion of treatment to see the sustained virological response. Results: There were 26 cases in total, with a mean age of 9.26 ± 2.82 years; 14 were males (53.8%), and 12 females (46.2%). Twenty-five (96.15%) patients achieved a sustained virological response, and the end-of-treatment PCR was negative. One patient (3.85%) was a nonresponder even after 24 weeks of treatment. The medication was well received, with only four patients (15.3%) reporting headaches that were reported untreated. Conclusion: The combination of sofosbuvir and ribavirin is effective in treating chronic HCV infection and is not accompanied by any major negative side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.